Blakkisrud, Johan, et al. “Myelosuppression in Patients Treated With 177Lutetium-Lilotomab Satetraxetan Can Be Predicted With Absorbed Dose to the Red Marrow As the Only Variable”. Acta Oncologica, vol. 60, no. 11, Nov. 2021, pp. 1481-8, doi:10.1080/0284186X.2021.1959635.